Cross Country Healthcare reported strong Q3 2022 results, exceeding updated guidance ranges for revenue, Adjusted EBITDA, and Adjusted EPS. The company saw double-digit year-over-year revenue growth across both segments and repurchased 1 million shares of common stock. Consolidated revenue was $636.1 million, a 70% increase year-over-year, and net income attributable to common stockholders was $34.8 million.
Revenue, Adjusted EBITDA, and Adjusted EPS exceeded previously updated guidance ranges.
Double-digit year-over-year revenue growth was achieved across both segments.
Adjusted EBITDA margin was 10.0%.
1 million shares of common stock were repurchased for $24.3 million.
The company provided guidance for Q4 2022, expecting revenue between $590 million and $600 million, a gross profit margin between 22.3% and 22.8%, Adjusted EBITDA between $52.0 million and $57.0 million, and Adjusted EPS between $0.85 and $0.95.
Visualization of income flow from segment revenue to net income